BOSTON, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ:DMRA) ("Damora"), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced
-- CLARITY-101 Phase 1/1b clinical trial initiated and cleared by multiple global regulatory authorities, includingthe U.S. Food and Drug Administration (FDA) -- -- New preclinical data highlighting DMR-001’s
-- Building on previously presented DMR-001 preclinical data in Type 1 and Type 2 CALR mutations,new data to highlight strong activity against additional non-Type 1 mutations -- -- Trial-in-progress presentation to
BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ:DMRA) ("Damora"), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced
BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ:DMRA) ("Damora"), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced
– Initiated the Phase 1/1b CLARITY-101 clinical trial of DMR-001 in patients with mutant calreticulin (mutCALR)-driven essential thrombocythemia (ET) and myelofibrosis (MF) – – Presented DMR-001 preclinical data at
-- DMR-001 is a highly potent, long-acting antibody therapy targeting Type 1 and non-Type 1 mutant calreticulin (mutCALR), designed for convenient once-monthly subcutaneous dosing -- -- In preclinical studies, DMR-001
BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ:DMRA) ("Damora"), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced
BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (Damora or the Company) (NASDAQ:DMRA), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today
BOSTON, July 01, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ:DMRA) ("Damora"), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced
BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ:DMRA) ("Damora"), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it
– DMR-001 preclinical data showcasing potentially best-in-class potency, half-life and anti-mutCALR activity to be presented at 2026 European Hematology Association Congress – – On track to submit first regulatory
BOSTON, May 01, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ:DMRA) ("Damora"), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it
BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ:DMRA) ("Damora"), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it
-- Ms. Jarrett brings nearly three decades of executive leadership in biotech, tech and finance -- -- Biotech leaders Dr. Cameron Turtle and Mike Landsittel appointed to Board of Directors -- -- Peter Harwin named
